Oncolytic
viral
therapy
represents
promising
strategy
treatment
head
neck
squamous
cell
carcinoma
(
HNSCC
)
,
dl1520
(
ONYX-015
)
widely
used
oncolytic
adenovirus
clinical
trials
.

This
study
aimed
determine
effectiveness
Lister
vaccine
strain
vaccinia
virus
well
vaccinia
virus
armed
endostatin-angiostatin
fusion
gene
(
VVhEA
)
novel
therapy
HNSCC
compare
dl1520
.

The
potency
replication
Lister
strain
VVhEA
expression
function
fusion
protein
determined
human
HNSCC
cells
vitro
vivo
.

Finally
,
efficacy
VVhEA
compared
dl1520
vivo
human
HNSCC
model
.

The
Lister
vaccine
strain
vaccinia
virus
effective
adenovirus
HNSCC
cell
lines
tested
vitro
.

Although
potency
VVhEA
attenuated
vitro
,
expression
function
endostatin-angiostatin
fusion
protein
confirmed
HNSCC
models
vitro
vivo
.

This
novel
vaccinia
virus
(
VVhEA
)
demonstrated
superior
antitumor
potency
vivo
compared
dl1520
control
vaccinia
virus
.

This
study
suggests
Lister
strain
vaccinia
virus
armed
endostatin-angiostatin
fusion
gene
may
potential
therapeutic
agent
HNSCC
.

